



P53-Therapeutics, Inc. Announces Eight Appointments to Scientific Advisory Board


[Philadelphia, Pennsylvania, July 26, 2024] – p53-Therapeutics, Inc. introduces eight internationally recognized leaders in oncology, cancer research, p53 biology and novel cancer therapies who recently joined its Scientific Advisory Board.



Laura Attardi, PhD
Stanford



Fred Bunz, MD, PhD
Johns Hopkins



Timothy F. Burns, MD, PhD
U. Pittsburgh



Keith Flaherty, MD
Harvard/MGH



Elsa Flores, PhD
Moffitt Cancer Center



Roy S. Herbst, MD, PhD
Yale University



Razelle Kurzrock, MD
Med. Coll. Wisconsin



Vivek Subbiah, MD
Sarah Cannon Res. Inst.

Newly appointed Scientific Advisory Boards Members include:

Laura Attardi, PhD: Dr. Attardi is Professor of Radiation Oncology and Genetics at Stanford University. Her focus is at the forefront of p53 tumor suppressor research that is defining mechanisms by which p53 functions normally, in stress, and in the setting of chemotherapeutics. She uses mouse models to gain insight to facilitate clinical advances in diagnosis, prognostication and therapy.

Fred Bunz, MD, PhD: Dr. Bunz is Associate Professor of Radiation Oncology and Molecular Radiation Sciences at the Johns Hopkins University. Dr. Bunz's research is unraveling how stress-activated signaling pathways affect the cellular responses to anti-cancer therapy. Recent work in the lab is focused on understanding the mechanistic basis for p53 effects in neoantigen-specific anti-cancer immune responses. His long-term goal is to better understand how current therapies work, and to develop new and improved cancer treatments.

Timothy F. Burns, MD, PhD: Dr. Burns is Associate Professor of Medicine at the University of Pittsburgh Hillman Cancer Center. Dr. Burns' research and clinical interests revolve around the development of targeted therapies for KRAS-mutant NSCLC as well as novel strategies to overcome resistance to targeted therapies for EGFR-mutant and MET-altered NSCLC. Earlier in his career, Dr. Burns focused on the tumor suppressive function of p53 including underlying mechanisms and therapeutic opportunities.

Keith Flaherty, MD: Dr. Flaherty is Professor of Medicine at Harvard Medical School, Director of the Henri and Belinda Termeer Center for Targeted Therapy, Director of Clinical Research, Cancer Center, Massachusetts General Hospital, Harvard University. Dr. Flaherty's research focuses on the understanding of novel, molecularly targeted therapies in cancer. In this context he focused on the development of response and predictive biomarkers to define the mechanisms of action and resistance of novel therapies, as well as to identify the optimal target population.



Elsa Flores, PhD: Dr. Flores is the Associate Center Director for Basic Science at the Moffitt Cancer Center. Dr. Flores' laboratory is working to understand the p53 family pathway to target this pathway therapeutically when it is mutated in cancer. She is unraveling the overlapping and unique activities of the p53 family in human cancer using mouse models and patient derived tumors. The work from her laboratory indicates that the inter-related functions of the p53 family members must be understood for effective therapy of tumors with alterations in the p53 pathway.

Roy S. Herbst, MD, PhD: Dr. Herbst is the Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology, Deputy Director at Yale Cancer Center, Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, Assistant Dean for Translational Research, Yale School of Medicine. Dr. Herbst is nationally recognized for his leadership and expertise in lung cancer treatment and research. He is best known for his work in developmental therapeutics and the personalized therapy of non-small cell lung cancer, particularly the process of linking genetic abnormalities of cancer cells to novel therapies.

Razelle Kurzrock, MD: Dr. Kurzrock is the Linda T. and John A. Mellowes Endowed Chair of Precision Oncology, Professor of Medicine and Associate Director of Clinical Research at the Medical College of Wisconsin Cancer Center. Dr. Kurzrock is a world-renowned leader in precision oncology and rare cancers research. She is recognized as one of the world's 25 most important voices in precision medicine and one of the most highly cited scientists globally having authored over 950 scientific and medical publications. Dr. Kurzrock is the Chair for the Early Therapeutics and Rare Cancers Committee (SWOG NCI) — one of the largest clinical trials cooperative groups in the country — and has been the principal investigator for more than 100 early-phase clinical trials, leading eight life-changing drugs to FDA approval.

Vivek Subbiah, MD: Dr. Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute. Dr. Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and lead the BRAF and RET tissue agnostic studies to FDA approval.

"We are delighted to welcome our highly distinguished colleagues as they join our Scientific Advisory Board," expressed **Wafik El-Deiry, MD, PhD, FACP**, Scientific Founder and Chairman of p53-Therapeutics. "Their tremendous expertise will help advance innovative treatments restoring a key tumor suppressor pathway in human cancer."

"The SAB appointments highlight p53-Therapeutics' commitment to the most expert input in the world as we bring new therapies to the field of oncology," said **Wolfgang Oster, MD, PhD**, Co-Founder and CEO of p53-Therapeutics. Dr. Oster also stated "I am excited to be working with Dr. Wafik El-Deiry who is the Director of the Legorreta Cancer Center at Brown University, an American Cancer Society Research Professor, and Chair of the Worldwide Innovative Network (WIN) Consortium in Precision Oncology. I believe Dr. El-Deiry is the most qualified p53 translational cancer investigator in the world with a global reach in oncology that is tremendously helpful to make needed progress."

Biographies of the SAB Members are available on the p53-Therapeutics Company website.

About p53-Therapeutics, Inc.:

P53-Therapeutics, Inc. is developing a new class of small molecule cancer therapeutics to effectively bypass mutations in the p53 tumor suppressor gene to treat patients with cancer. *TP53* mutations occur frequently across tumor types. *TP53* is mutated in most human cancers and at an even higher frequency among difficult to treat cancers and in patients that fail first-line therapies. Particularly high mutation rates occur in head and neck, ovarian, colorectal, lung and brain cancer among others. P53-Therapeutics uses a novel approach with candidate drugs that biochemically and functionally modulate this most important cancer pathway to address therapy resistance in the clinic. The Company is developing molecules to target a broad range of p53-mutated cancers based on compelling pre-clinical safety, efficacy and biomarker data with line of sight to IND filing and strong IP position. The Founders of p53-Therapeutics, Inc., Drs. El-Deiry and Oster have worked together since 2007, including previous value creation for Oncocutics, Inc. starting from early preclinical stages through first-in-human and phase II studies to exit. P53-Therapeutics is planning to conduct a first-in-human study with a proprietary p53-bypassing drug candidate within its extensive portfolio.